Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96H20
UPID:
SNF8_HUMAN
Alternative names:
ELL-associated protein of 30 kDa; ESCRT-II complex subunit VPS22
Alternative UPACC:
Q96H20; Q8IXY3; Q9UN50
Background:
Vacuolar-sorting protein SNF8, also known as ELL-associated protein of 30 kDa or ESCRT-II complex subunit VPS22, plays a crucial role in the endosomal sorting complex required for transport II (ESCRT-II). This complex is essential for multivesicular body (MVB) formation and the sorting of endosomal cargo proteins into MVBs, which are pivotal for the degradation of transmembrane proteins in the lysosome. SNF8 is involved in the recruitment of the ESCRT-III complex and may influence transcription regulation through its interaction with ELL. It is vital for the degradation of endocytosed EGF and EGFR, and the exosomal release of SDCBP, CD63, and syndecan.
Therapeutic significance:
Understanding the role of Vacuolar-sorting protein SNF8 could open doors to potential therapeutic strategies.